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Abstract
Patients with end stage renal diseases (ESRD) are generally tested for donor chimerism after kidney transplantation for
tolerance mechanism purposes. But, to our knowledge, no data are available on natural and/or iatrogenic microchimerism
(Mc), deriving from pregnancy and/or blood transfusion, acquired prior to transplantation. In this context, we tested the
prevalence of male Mc using a real time PCR assay for DYS14, a Y-chromosome specific sequence, in peripheral blood
mononuclear cells (PBMC) from 55 women with ESRD, prior to their first kidney transplantation, and compared them with
results from 82 healthy women. Male Mc was also quantified in 5 native kidney biopsies obtained two to four years prior to
blood testing and in PBMC from 8 women collected after female kidney transplantation, several years after the initial blood
testing. Women with ESRD showed statistically higher frequencies (62%) and quantities (98 genome equivalent cells per
million of host cells, gEq/M) of male Mc in their PBMC than healthy women (16% and 0.3 gEq/M, p,0.00001 and p=0.0005
respectively). Male Mc was increased in women with ESRD whether they had or not a history of male pregnancy and/or of
blood transfusion. Three out of five renal biopsies obtained a few years prior to the blood test also contained Mc, but no
correlation could be established between earlier Mc in a kidney and later presence in PBMC. Finally, several years after
female kidney transplantation, male Mc was totally cleared from PBMC in all women tested but one. This intriguing and
striking initial result of natural and iatrogenic male Mc persistence in peripheral blood from women with ESRD raises several
hypotheses for the possible role of these cells in renal diseases. Further studies are needed to elucidate mechanisms of
recruitment and persistence of Mc in women with ESRD.
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Introduction
Microchimerism (Mc) is the presence of a small amount of
foreign cells or DNA within a person’s circulation or tissues [1].
Mc can be acquired through iatrogenic interventions such as
organ transplantation, first described in liver transplantation in
1969 [2], or blood transfusion [3]. Mc can also be naturally
acquired during pregnancy due to feto-maternal traffic of cells
through the placenta membrane [4]. Interestingly, these cells are
not short term transitory cells as they can persist for decades in
small quantities in their respective hosts [5]. Exchange of cells
between fetuses can also contribute to natural Mc within an
individual. They were first described between bovine dizygotic
twins [6] and later in humans [7]. Recently, our group even
reported the presence of cells from an unrecognized (vanished)
twin in a 40-year-old man diagnosed with a scleroderma-like
disease [8].
The natural phenomenon of Mc has already been investigated
in whole peripheral blood [9], peripheral blood mononuclear cells
(PBMC) [10] and different tissues [11] from healthy women and
women with autoimmune diseases as scleroderma, dermatomyo-
sitis, thyroiditis [12,13,14,15]… Higher quantities and frequencies
of male Mc observed in women with scleroderma compared to
matched controls suggested a possible role for these cells in
autoimmunity [12]. However it is still unclear whether the
presence of Mc is the cause or the consequence of autoimmunity,
whether natural Mc is present to heal or to kill (for reviews
[16,17]). For example, in breast cancer, Mc was seen as a
protective factor in a study by Gadi et al., where the risk of cancer
was lower in women positive for male Mc at the peripheral level
[18], whereas in another study, on human breast carcinoma
developing during pregnancy, presence of fetal Mc in tumor
sections suggested these cells played a detrimental role [19].
Evaluation of the role of fetal Mc in the context of renal diseases
was mostly studied indirectly. Indeed fetal cells have been found
twice as often in kidneys from women with systemic lupus
erythematosus (SLE) than in normal kidneys [20], suggesting that
they could play a role in renal disease and/or renal function. A
prior study in patients with SLE noted a higher mean number of
male equivalent cells in peripheral blood from patients with renal
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equivalent cells vs 0.89 male equivalent cells respectively; p,0.05)
[21].
When chimerism is studied in patients with renal diseases it is
generally to analyze the influence of donor Mc after kidney
transplantation for tolerance mechanism purposes [22], and not to
analyze the potential role and fate of natural and/or iatrogenic Mc
acquired prior to transplantation.
In this context, we studied the unexplored phenomenon of Mc
in women with end stage renal diseases (ESRD) prior to their first
kidney transplantation, by using a quantitative PCR method for
male Mc detection in their PBMC. Male Mc quantification was
estimated according to the source of chimerism, pregnancy or
transfusion, and compared to results obtained from healthy
women.
Methods
Participant’ characteristics
Fifty-five women awaiting their first kidney transplantation and
82 healthy women were studied. Controls and patients came from
the same geographical area between Marseille and Nice, in the
south east of France.
All 55 women with chronic kidney disease were hemodialyzed
except for 4 with a Cockroft and Gault creatinine clearance
,15 ml/min at the time of DNA extraction. The initial
nephropathies were interstitial (n=21), glomerulonephritis
(n=11), polycystic kidney disease (n=9), nephroangiosclerosis
(n=4), lupus nephritis (n=3), diabetes type I (n=2), diabetes type
2 (n=2), hemolytic-uremic syndrome (n=2), indeterminate
(n=1). This proportion is similar to those described in
transplanted patients by the French ESRD Registry REIN 2009.
Women with ESRD and healthy women were very similar for
pregnancy history and differed for transfusion history (leuko-
reduced) as detailed in Table 1.
Ethics Statements
All controls were healthy women with no history of autoim-
mune disease or kidney disease. These healthy women have been
used as controls in a previous published study [23]. This study
received the approval from the French Ethical Committee
Marseille 2 and is registered at the INSERM under the Biomedical
Research Protocol number RBM-04-10. Written consent forms
obtained according to the Declaration of Helsinki [24] were
signed. Questionnaires with detailed information about previous
transfusions, pregnancies, and existence of an older brother (as a
possible source of male Mc) were filled in for each participant of
the study. For one healthy control, we were not able to obtain all
the information. Samples from women with ESRD were collected
for HLA-typing before registration on the waiting list and then for
microchimerism detection which was performed as a ‘‘res nullus’’
analysis. Patients were informed and acquiescent.
DNA extraction from PBMC and native kidney
parenchyma
DNA extractions from PBMC for women with ESRD were
performed prior to the extractions from controls obtained for a
different study. Genomic DNA from patients was extracted using a
‘‘salting-out’’ method [25], from PBMC after EDTA blood
processing by Ficoll Histopaque 1077 gradient centrifugation
(Sigma-Aldrich, St Louis, MO, USA). Genomic DNA was
quantified and purity was assessed by spectrophotometric
absorbance at 260 and 280 nm.
Genomic DNA from controls was extracted from PBMC after
EDTA blood processing by Ficoll Histopaque 1077 gradient
centrifugation (Sigma-Aldrich, St Louis, MO, USA). DNA
isolation was done with an EZ1 DNA Tissue Kit (Qiagen, Hilden,
Germany) on a BIOROBOTH EZ1 according to the manufac-
turer’s instructions.
Aware that different DNA extraction methods between the two
groups could lead to different results for Mc, 9 patients with ESRD
with blood taken more recently had their DNA extracted with a
similar method to healthy women (Qiagen kit) and were tested as a
separate group to verify whether different methods lead to
different results (see results).
For 5 patients, renal tissues from native kidneys were obtained
by transcutaneous biopsy and cryopreserved. DNA was extracted
with an EZ1 DNA Tissue kit (Qiagen, Hilden, Germany) as
described above.
DYS14 real time quantitative PCR
Quantification of male Mc was obtained by real-time PCR for a
Y-chromosome specific sequence DYS14 on a Light CyclerH with
Light CyclerH Fast Start DNA MasterPLUS Reaction kits (Roche,
Indianapolis, IN, USA) as previously described [23]. Total amount
of tested DNA was measured by ß-globin, a house keeping gene, as
previously described [13]. Duplicates of ß-globin were averaged
Table 1. Characteristics from healthy women and women with ESRD.
Characteristics Women with ESRD (N=55) Healthy women (N=82) P values
Median age, range 50[14–67] 52 [37–69] ns
Mean number of children 2 2 (N=81)
a ns
Mean number of sons 1 1(N=81) ns
% of women with at least one son 69 62 (N=81) ns
Mean age of the youngest son 19 21 (N=81) ns
% of nulligravid women 10 6 (N=81) ns
% of women with early pregnancy loss 43 53 (N=81) ns
% of women with blood transfusion 65 12 ,0.0001
Mean number of transfusions 1 0 ,0.0001
Years since last transfusion: mean, [range] 5.6 [0.5–30] 24.5 [17–36] ,0.0001
apregnancy and transfusion information was incomplete for one healthy woman. ns: not significant.
doi:10.1371/journal.pone.0032248.t001
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multiplied by the number of wells tested.
Sensitivity of the DYS14 assay was accurate to the equivalent
DNA of 1 male cell in a background equivalent DNA of 20,000
female cells. DNA from each participant was tested in ten samples
with a DNA equivalent of 20,000 cells by real-time PCR for ß-
globin (equivalent of 200,000 cells tested/woman). For ease of
result legibility, the amount of male DNA was expressed as the
number of genome equivalent male cells per million female cells
(gEq/M). Because the male Mc in each well is assumed to have a
Poisson distribution, the male genome equivalent cells for each
subject were averaged as previously described [23]. The estimate
for individuals for whom all replicates are assayed using the same
number of cells per replicate is the usual Poisson estimate: 2ln
(12p)/M where p is the fraction of samples with at least 1 male cell
(the limit of p being 1 well positive out of 10 tested) and M is the
number of cells in the sample (20,000 in our case). The confidence
limit for calculation is when 1 well is positive out of 10, this is why
as a conservative estimate of the quantity of male DNA, we
required that a sample had at least two wells out of ten positive.
Extreme caution was employed to avoid PCR contamination:
women performed all the technical work. Pre-amplification steps
were carried out in a separate room. A negative control sample
was included in each experiment.
Statistical analysis
Significant differences between the two groups were detected
using the Chi square test for qualitative variables (Fisher exact test)
and an unpaired t-test for continuous variables with a normal
distribution or if not, a non-parametric test i.e a Wilcoxon signed-
rank test and a Mann-Whitney test for paired series using Statview
5 software (SAS Institute Inc;Cary, NC; USA). Logistic regression
was used to assess a relationship between renal status and the
presence of male DNA. For all tests, statistical significance was
defined as p,0.05.
Results
Increased frequency and higher quantities of male Mc in
PBMC from women with ESRD compared to controls
When both groups were analyzed as a whole, without stratifying
by age, parity, or history of transfusion, as illustrated in Figure 1,
we detected male Mc in 62% (34/55) of women with ESRD versus
only 16% (13/82) of healthy women (p,0.00001). Differences in
quantities of Mc between the two groups were also very significant
(Figure 1, Figure 2 for typical amplifications and Table S1 for
number of wells positive). Levels of Mc ranged from 0 to
1382 gEq/M in women with ESRD and from 0 to 5 gEq/M in
controls with a mean number of 98 gEq/M and 0.3 gEq/M
respectively (p=0.0005). We did not find any correlation between
Mc levels and the length of time since the last abortion, the
number of induced or spontaneous abortions, the length of time
since the last transfusion, the length of time since the birth of the
last child or last son, or the number of sons or children (data not
shown).There was also no relationship between the types of
nephropathy (vascular, glomerular, interstitial and polycystic) and
the presence or the level of Mc (data not shown).
As differences in DNA extraction methods between women with
ESRD and healthy women could introduce artifacts for Mc results,
we analyzed a separate subgroup of 9 patients with ESRD with
blood taken more recently, for whom DNA extraction methods
were identical to healthy controls. Frequency of women positive
for Mc was statistically significant in this subgroup of patients with
ESRD (Fisher’s exact test, p=0.013), with 5 out of 9 women with
Figure 1. Male Mc quantities in PBMC from women with ESRD
and healthy women.
doi:10.1371/journal.pone.0032248.g001
Figure 2. Typical amplifications of male Mc in female host’s
DNA. PBMC from a healthy woman (A) and a woman with ESRD (B)
tested for male Mc in 10 samples.
doi:10.1371/journal.pone.0032248.g002
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Mc were also significantly increased (Mann Whitney, p=0.0006)
with respectively a mean of 57.0 gEq/M [95% CI: 212.46–126.6]
and 0.3 gEq/M [95%.CI: 0.11–0.54]. Results of this sub-analysis
exclude a possible bias due to different DNA extraction methods.
Frequencies and quantities of Mc are increased in
women with ESRD whether they had or not a history of
male pregnancy and/or of transfusion
Male Mc could come from natural or iatrogenic source; we
therefore classified women with ESRD and healthy women
according to whether they had or not a transfusion history and
they had or not given birth to at least one son (Table 2). Non-
transfused (TSF2) women with ESRD had male Mc more often
than healthy matched controls, regardless of whether they had
given birth to a son or not (S+ or S2), with respectively 50% and
71% compared with 18% and 14% (p=0.02 and p=0.001
respectively). Moreover quantities of male Mc were higher in non-
transfused women with ESRD compared to matched healthy
women and again differences were not due to pregnancy history as
results were similarly significant whether they had or not given
birth to at least one son (p=0.0019 and ,0.0001 respectively).
Similarly, transfused (TSF+) women with ESRD also had male
Mc more often and in higher quantities than healthy matched
controls whether they had given birth to a son, with only the
former case (S+) that could be statistically evaluated (p=0.008)
due to small numbers in the latter case (S2).
Male Mc in kidney biopsies two to four years prior to
blood testing
Five women were investigated for male DNA in their kidney
parenchyma (Table 3). Renal tissues were obtained from kidney
biopsies with a median time of 36 months (range from 24 to 48)
prior to blood testing. Among the five patients, 1 had anti-
neutrophil cytoplasmic antibodies (ANCA), 2 had systemic lupus
erythematosus (SLE), 1 hemolytic-uremic syndrome (HUS), and 1
focal glomerulosclerosis (FSGS). Two of the five patients were
negative for male Mc in renal parenchyma and a few years later
had either 10 gEq/M in their PBMC or no male Mc. Three
women carried male DNA at concentrations of 30, 10 and 3 gEq/
M in renal tissue and a few years later had respectively 21, 2 and
474 gEq/M in their PBMC. No correlation was found between
earlier levels in kidney biopsies and later levels of Mc in PBMC.
Clearance of male Mc after kidney transplantation in
PBMC from 8 women with ESRD (Table 4)
Finally, we quantified male Mc in PBMC from 8 women with
ESRD who had received a female kidney transplant (so as not to
complicate Mc sources). At the time of DNA extraction from
PBMC, all 8 kidney grafts were functional with a glomerular
filtration rate (GFR) ranged from 25 to 70 ml/min. The
immunosuppressive protocol consisted in an induction by anti-
lymphocyte serum in all patients and triple drugs regimen
(steroids, calcineurin inhibitors and mycophenolic acid) therapy.
PBMC analysis was carried out in a median time of 4.6 years after
transplantation. Among the 8 women tested, 3, negative in their
PBMC prior to transplantation remained negative after trans-
plantation, 5 positive before transplantation with, from the lowest
to the highest results: 5, 14, 21, 45 and 1,149 gEq/M were all
negative after transplantation except the third patient who had
6 gEq/M in her PBMC. Using a Wilcoxon signed-rank test, which
is a non-parametric test, we found a marginal decrease (p=0.04)
of Mc levels in the pre to post transplantation period.
Discussion
We present the first study analyzing male Mc in PBMC from
women with end stage renal disease (ESRD), prior to their first
kidney transplantation. Male Mc was found significantly more
often and at higher concentrations than in healthy women.
Samples were collected from two independent studies and DNA
extractions obtained by different methods, which could introduce
artefacts in the results. Noteworthy, divergences between methods
have been demonstrated with circulating DNA from plasma or urine
samples, where small DNA fragments were lost [26] depending on
DNA extraction methods but not from cell DNA samples.
However to eliminate any suspicion, we tested independently a
subgroup of 9 patients for whom DNA was extracted with a similar
method to healthy women and found similar results to those
obtained in the main group of women with ESRD.
Women with ESRD often have a history of leuko-reduced blood
transfusion which could leave iatrogenic Mc as a post transfusion
consequence and trigger higher levels of male Mc, when the donor
was male [3]. However, we demonstrated that the difference for
Mc frequency and/or quantity observed in women with ESRD
was not dependent on transfusion history, as results remained
significant in women who had never had a blood transfusion.
Intriguingly, the difference observed did not correlate either with
Table 2. Male Mc in women with ESRD and healthy women according to pregnancy and transfusion history.
Analyzed group
Women positive
for Mc # (%)
Frequency
p-values
Mean quantity of male Mc (gEq/M)
[range]; Median Quantity p-values
TSF2S+ Controls (N=44) 8 (18%) 0.3 [0–5]; 0
ESRD (N=12) 6 (50%) 0.05 36.5 [0–247]; 2 0.0019
TSF2S2 Controls (N=28) 4 (14%) 0.4 [0–4]; 0
ESRD (N=7) 5 (71%) 0.006 37.4 [0–101]; 28 ,0.0001
TSF+S+ Controls (N=7) 0 (0%) 0
ESRD (N=26) 17 (65%) 0.003 130 [0–1149]; 16.5 0.008
TSF+S2 Controls (N=3) 1 (33%) 0.6 [0–2]; 0
ESRD (N=10) 6 (60%) No stats * 192.2 [0–1382]; 4.5 No stats*
TSF+: women who had received at least one blood transfusion; TSF2: women who had never received a blood transfusion; S+: women who had given birth to at least
one son; S2: women who had never given birth to a son (S2);
*no stats: statistical analyses were not done due to small numbers.
doi:10.1371/journal.pone.0032248.t002
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influence on the results. Furthermore, women with ESRD who
had never had a blood transfusion and never given birth to a son
had male Mc more often in their PBMC and at higher quantities
than healthy matched controls. These surprising results suggest
they have male DNA from an incomplete pregnancy and/or an
unrecognized twin as previously discussed in other studies relative
to Mc [27,28]. Indeed, a non-negligible number of pregnancies
end before they are clinically noticed [29] and unrecognized
twinning is relatively common in healthy pregnancy [30]. In a
recent study, Kremer Hovinga et al., also suspected such non-
classical sources as principal causes for Mc in renal biopsies from
women with lupus nephritis as they showed no significant
difference between the occurrence of chimerism in the biopsies
of women who had been pregnant compared with women who
had not been pregnant [31].
Several hypotheses, not necessarily exclusive, could explain the
higher prevalence of male Mc in women with ESRD before kidney
transplant compared to healthy women.
First, high levels of male Mc observed in peripheral blood
mononuclear cells could indicate a decreased capacity to eliminate
male DNA, a consequence of ESRD by decrease of glomerular
filtration rate. Very little is known about the life cycle, persistence
and elimination process of foreign or semi-foreign cells within an
individual. It has been shown that fetal DNA disappears from
peripheral blood right after delivery in a very rapid, probably
immunological and/or renal, process [32]. Moreover, male DNA
has been found in female urine in several cases: after male kidney
transplantation and during pregnancy with male fetuses [33].
However, it is still unknown how DNA crosses the normal kidney
barrier and appears in the filtrate. Our initial results, on peripheral
blood from 8 women who had received a female kidney transplant
more than 4 years before, seem to argue in favour of a recovered
capacity to eliminate male Mc after transplantation. Indeed women
with ESRD who were previously positive for male Mc became
negative after kidney transplant. However it is still speculative to
consider that clearance of male DNA observed post-transplant in
PBMC is due to restored kidney function, as patients undergoing
kidney transplant are under strong immunosuppressive drugs that
could also affect microchimerism levels. Illustrating this, we recently
found, in women with Rheumatoid Arthritis, fluctuating levels of
Mc coinciding with disease flare up and treatment [34].
A second hypothesis for high levels of Mc in blood could be a
consequence of inflammation in dialysis as well as ESRD patients.
It has been recognized that 30% to 50% of pre-dialysis,
hemodialysis and peritoneal dialysis patients have serological
evidence of an activated inflammatory response [35]. Many
mechanisms can induce an inflammatory condition such as
reduced renal clearance of cytokines, accumulation of advanced
glycation end-products (AGEs), chronic heart failure, atheroscle-
rosis per se, unrecognized persistent infections with additional
causes in dialysis such as fistula infection and bioincompatibility of
dialysis membrane, exposure to endotoxins [35]. High levels of
cytokines and chemoattractants may possibly recruit fetal cells
from their niche, for example from bone marrow or lymph nodes
[36,37]. Here again the quasi-absence of Mc in PBMC after
kidney transplantation could come from decreased inflammation
due to strong immuno-suppression targeting T lymphocytes.
Table 3. Quantification of Mc in kidney biopsies prior to transplantation from five women with ESRD.
Patients Kidney disease
Results of male Mc
in kidneys (gEq/M)
Year of kidney
biopsy
Results of male Mc in
PBMC (gEq/M) Year of blood test
Months between kidney
biopsy and blood test
1 ANCA* 30 1999 21 2002 36
2 SLE 0 2003 10 2005 24
3 SLE 0 1999 0 2002 36
4 HUS 10 2000 2 2004 48
5 FSGS 3 2000 474 2002 36
*ANCA: antineutrophil cytoplasmic antibodies, SLE: systemic lupus erythematosus; HUS: hemolytic-uremic syndrome, FSGS: Focal segmental glomerulosclerosis.
doi:10.1371/journal.pone.0032248.t003
Table 4. Quantification of male Mc in PBMC from 8 women with ESRD after female kidney transplantation.
Patients Male Mc in PBMC (gEq/M)
Years after
transplantation
GFR* (ml/min) at the time of post-
transplant blood test
before transplantation after transplantation
1 1149 066 7
20 0 5 5 3
3 14 066 0
4 21 6 54 9
50 0 3 2 5
6 45 075 9
70 0 4 4 4
8 5 053 2
*GFR: glomerular filtration rate.
All patients from this table are different from patients presented table 3, except Patient 4 who is Patient 1 in Table 3.
doi:10.1371/journal.pone.0032248.t004
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damaged tissue and high blood levels would only be reflecting
higher kidney levels. In a rat model, it has been described that fetal
cells could remodel the maternal kidney after injury [38].
Therefore, the presence of male Mc in kidneys, although at low
levels, could be a regenerative process. In our study, we were able
to obtain 5 native kidneys biopsies taken 24 to 48 months prior to
the blood test, at the time of diagnosis, and demonstrate that 3 out
of 5 tested were slightly positive for Mc, but we could not
demonstrate whether these cells belonged to the kidney or came
from blood vessels supplying the organ. This would have to be
determined in further analyses and was beyond the scope of the
current study.
Finally as a fourth hypothesis, fetal cells recruited under
inflammatory processes might not be bystanders in peripheral
blood, or helpers, but effector cells as suggested in a recent study
on kidney biopsies from patients with lupus nephritis. In these
biopsies microchimeric cells were indeed shown within the
hematopoietic stem cell phenotype (CD34+) as well as within T
lymphocytes [20].
As anticipated, there is no single explanation for our results
showing high levels of male Mc in women with ESRD. Even if we
speculate that Mc cells are recruited to help the damaged organ, it
is obvious that this help is not fully efficient, since the kidney is not
functional in the end. However, it is to be noted that a few studies
describe slower disease progression in women with chronic renal
disease compared to men, which could argue for a protective role
of Mc. Indeed, a meta-analysis involving 11,345 patients
determined a gender effect on kidney disease progression from
non-diabetic patients [39]. Men with autosomal dominant
polycystic kidney disease, membranous nephropathy, or chronic
kidney disease of unspecified etiology progressed to renal failure
more rapidly than women. Female protection from renal disease
progression is also observed in animal models of progressive renal
disease [40]. Little is known about the mechanisms underlying sex
differences in renal disease susceptibility [41] and it would be
interesting to investigate whether chimerism could contribute to a
certain ‘‘protection’’ and lead to a gender difference.
This article brings forward new original insights into the
unexplored phenomenon of Mc in renal diseases and should
initiate future research to determine mechanisms of recruitment
and persistence of Mc in patients with ESRD prior to kidney
transplantation.
Supporting Information
Table S1 Distribution of male Mc per 10 wells tested
among positive individuals. Mean number of positive wells
out of ten tested in women with ESRD: 5.85 (95% CI [4.928–
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